Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival

Version 1 : Received: 29 May 2024 / Approved: 29 May 2024 / Online: 30 May 2024 (09:28:36 CEST)

A peer-reviewed article of this Preprint also exists.

Andrzejczak, A.; Małkiewicz, B.; Tupikowski, K.; Ptaszkowski, K.; Szydełko, T.; Karabon, L. Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival. Int. J. Mol. Sci. 2024, 25, 6860. Andrzejczak, A.; Małkiewicz, B.; Tupikowski, K.; Ptaszkowski, K.; Szydełko, T.; Karabon, L. Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival. Int. J. Mol. Sci. 2024, 25, 6860.

Abstract

Renal cell carcinoma (RCC) accounts for approximately 90-95% of all kidney cancers in adults, with the clear cell RCC (ccRCC) the most frequently identified subtype. RCC is known for its responsiveness to immunotherapy, making it an area of significant research interest. Immune checkpoint (IC) molecules, which regulate immune surveillance, are established therapeutic targets in RCC. The aim of this study was to analyze the influence of polymorphisms in genes HVEM and CD160 on susceptibility to ccRCC and patient overall survival (OS) with over a ten-year period of observation. We genotyped three HVEM single nucleotide polymorphisms (SNPs): rs1886730, rs2234167, and rs8725, and two CD160 SNPs: rs744877 and rs2231375, in 238 ccRCC patients and 521 controls. Our findings indicated that heterozygosity within rs2231375 and/or rs2234167 increases ccRCC risk. Furthermore, in women, heterozygosity within additional HVEM SNPs, rs8725 and rs1886730, is associated with an increased ccRCC risk. The presence of a minor allele for rs1886730, rs2234167, rs8725, and rs2231375 was also correlated with certain clinical features of the disease. Moreover, the rs1886730 SNP was found to be associated with patients' OS. In conclusion, our study highlights an association between HVEM and CD160 polymorphisms and the risk of developing ccRCC as well as patient’s OS.

Keywords

HVEM; CD160; clear cell renal cell carcinoma (ccRCC); single nucleotide gene polymorphism (SNP); immunological checkpoint; disease risk; overall survival

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.